- Home
- INCY vs MBLY Comparison
INCY vs MBLY Comparison
Compare INCY & MBLY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INCY
- MBLY
- Stock Information
- Founded
- INCY 1991
- MBLY 1999
- Country
- INCY United States
- MBLY Israel
- Employees
- INCY N/A
- MBLY N/A
- Industry
- INCY Biotechnology: Commercial Physical & Biological Resarch
- MBLY Computer Software: Prepackaged Software
- Sector
- INCY Health Care
- MBLY Technology
- Exchange
- INCY Nasdaq
- MBLY Nasdaq
- Market Cap
- INCY 13.4B
- MBLY 14.4B
- IPO Year
- INCY 1993
- MBLY 2022
- Fundamental
- Price
- INCY $68.07
- MBLY $14.83
- Analyst Decision
- INCY Buy
- MBLY Buy
- Analyst Count
- INCY 19
- MBLY 22
- Target Price
- INCY $74.38
- MBLY $23.70
- AVG Volume (30 Days)
- INCY 1.8M
- MBLY 4.0M
- Earning Date
- INCY 04-29-2025
- MBLY 04-24-2025
- Dividend Yield
- INCY N/A
- MBLY N/A
- EPS Growth
- INCY N/A
- MBLY N/A
- EPS
- INCY 0.15
- MBLY N/A
- Revenue
- INCY $4,241,216,999.00
- MBLY $1,654,000,000.00
- Revenue This Year
- INCY $12.23
- MBLY $8.28
- Revenue Next Year
- INCY $8.89
- MBLY $17.76
- P/E Ratio
- INCY $454.93
- MBLY N/A
- Revenue Growth
- INCY 14.76
- MBLY N/A
- 52 Week Low
- INCY $50.35
- MBLY $10.48
- 52 Week High
- INCY $83.95
- MBLY $34.00
- Technical
- Relative Strength Index (RSI)
- INCY 38.27
- MBLY 40.68
- Support Level
- INCY $68.17
- MBLY $13.46
- Resistance Level
- INCY $72.81
- MBLY $15.93
- Average True Range (ATR)
- INCY 2.29
- MBLY 1.13
- MACD
- INCY -0.32
- MBLY -0.13
- Stochastic Oscillator
- INCY 8.61
- MBLY 28.07
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
About MBLY Mobileye Global Inc.
Mobileye Global Inc engages in the development and deployment of ADAS and autonomous driving technologies and solutions. It is building a portfolio of end-to-end ADAS and autonomous driving solutions to provide the capabilities needed for the future of autonomous driving, leveraging a comprehensive suite of purpose-built software and hardware technologies. The company's reportable operating segment are Mobileye and Others. Its solutions comprise Driver Assist, Cloud-Enhanced Driver Assist, Mobileye SuperVision Lite, Mobileye SuperVision, Mobileye Chauffeur, Mobileye Drive, Self-Driving System & Vehicles. It derives maximum revenue from Mobileye Segment.